Bacterial Vaginosis (BV) is one of the most common diseases in women. Traditional treatment primarily target female patients, but the high recurrence rate has remained a significant challenge. A groundbreaking study published in the New England Journal of Medicine has brought a breakthrough in this area: treating male partners can significantly reduce the recurrence rate of BV in women. This discovery not only changes the treatment paradigm for BV but also provides a new direction for new drug development.

Bacterial Vaginosis is an infection caused by an imbalance in the vaginal microbiota, with symptoms including unusual odor, abnormal discharge, and, in severe cases, complications such as pelvic inflammatory disease, infertility, and even preterm birth. Currently, the standard treatment for BV involves antibiotics (such as metronidazole or clindamycin), but up to 50% of patients experience a recurrence within six months after treatment. This high recurrence rate not only affects patients' quality of life but also places a heavy burden on healthcare systems. The study published in the New England Journal of Medicine is the first to suggest that BV may be transmitted through sexual activity, and male partners could be a potential source of recurrent infections in female patients. The study shows that when male partners are treated simultaneously, the recurrence rate in female patients is significantly reduced. This finding overturns traditional views, emphasizes the importance of partner-inclusive treatment, and offers a novel approach to the prevention and management of BV.

As a new drug development company in infectious disease area, TenNor has been committed to addressing unmet clinical needs in disease areas associated with bacterial infections and bacterial metabolism. On May 28, 2024, International Day of Action for Women's Health, the Journal of Medicinal Chemistry of the American Chemical Society published a special issue featuring 17 research articles focused on unmet clinical needs in women's health. TenNor's article on the use of TNP-2198 (rifasutenizol) for treating microaerophilic and anaerobic bacterial infections was included in this special issue, recognizing its contribution to advancing research in women's health.

For more details, visit: https://www.nationalgeographic.com/health/article/bacterial-vaginosis-sexually-transmitted.

特别申明：文章原引内容及涉及字体图片等素材版权归原作者所有。本文章内容仅用于学习及学术交流，不做任何商业用途。

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com